Article Text

Download PDFPDF

544 Patients with CHEK2 mutation followed up in a hereditary gynaecological cancer unit
  1. A Veiga-Fernández1,
  2. M Bernal Claverol1,
  3. M Ruiz Minaya1,
  4. I Aracil Moreno1,
  5. C Galvis Isaza1,
  6. M Díaz Perdigón1,
  7. Á Bretón Santos1,
  8. M Leñero Cirujano1,
  9. P Rincon Olbes1,
  10. E Mendizábal Vicente1,
  11. I Echavarria Díaz-Guardamino2 and
  12. S Lizarraga Bonelli1
  1. 1Gregorio Marañón University General Hospital, Obstetrics and Gynaecology, Madrid, Spain
  2. 2Gregorio Marañón University General Hospital, Medical Oncology, Madrid, Spain


Introduction/Background*CHEK2 gene is located on chromosome 22 and participates in the maintenance of the genome and control of the cell cycle and apoptosis. Mutations in this gene are considered to increase the risk of breast cancer. An accumulated risk throughout life is estimated at 28-37% in these patients.

Retrospective observational study Review of patients followed in the inherited cancer unit in a single tertiary centre between 1st January 2012 until 28th February 2021.

The statistical analysis was carried out using SPSS 22.0.

Result(s)*During the indicated period, we followed 401 patients with confirmed genetic mutations that predispose to developing gynaecological cancer. Of the total, 2.49% (10/401) were carriers of a CHEK2 mutation.

Within the cohort of patients carrying a CHEK2 mutation, 7/10 (70%) had a family history of breast cancer and 1/10 (10%) a gastric cancer. 6/10 patients were diagnosed with breast cancer at 23, 37, 37, 38, 44 and 52 years old. One of them had a second contralateral breast cancer at age 47.

The histology of the breast cancer was either ductal carcinoma in situ or invasive ductal carcinoma. Tumor stage was 0 in one case, I in one case, IIA in two cases and IIIA in two cases. Surgery treatment was: unilateral mastectomy with homolateral axillary lymphadenectomy in 3 patients, conservative surgery in 1 patient, conservative surgery with selective sentinel lymph node biopsy in 1 patient and conservative surgery with homolateral axillary lymphadenectomy in 1 patient. Adjuvant treatment was: chemotherapy and hormone therapy in one case, radiation therapy and chemotherapy in one case, radiation therapy and hormone therapy in one case and radiation therapy, chemotherapy and hormone therapy in the other two.

Characteristics of these patients are summarized in table 1.

Abtract 544 Table 1

Discussion There are several recommendations in the literature regarding the follow-up of patients carrying a CHEK2 mutation.

In general, it is recommended that all female carriers should be offered intensified surveillance programs for breast cancer including annual breast radiological testing.

Conclusion*Patients carrying CHEK2 mutations have a moderate risk of developing breast cancer and should be followed in specialized hereditary cancer units.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.